Phase 3 ATOMIC trial Updates: Atezolizumab plus FOLFOX for Stage III dMMR Colon Cancer
oncodaily - Patients with stage III colon cancer are typically treated with surgical resection followed by adjuvant chemotherapy with a fluoropyrimidine-plus-oxaliplatin regimen. However, approximately 30% of patients with stage III disease experience […]
AI Summary: Phase 3 ATOMIC updates show that adding atezolizumab to FOLFOX/mFOLFOX6 improves disease‑free survival in patients with Stage III dMMR colon cancer, with a substantial reduction in recurrence risk reported. The results suggest immunotherapy may become integral to adjuvant treatment for this biomarker‑defined subgroup.
- ATOMIC breakthrough: atezolizumab reduces recurrence in dMMR colon patients (3)
- From the wards: MSI-H immunotherapy expands beyond colon (3)
- On the frontline: colorectal biomarkers and therapy innovations (6)
- Other headlines: cancer research news outside ATOMIC focus (1)
- All Other Stories
ATOMIC breakthrough: atezolizumab reduces recurrence in dMMR colon patients
From the wards: MSI-H immunotherapy expands beyond colon
On the frontline: colorectal biomarkers and therapy innovations
Other headlines: cancer research news outside ATOMIC focus
All Other Stories
Related Stories
Merck and Moderna report positive phase‑3 melanoma vaccine results / 6 wks
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 6 wks
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 1 month
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 3 months
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 3 months
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Genetics, Clinical Trials, Zoonotic Disease, Oncology and look for the RSS link.
StackHealth Time Machine